EBR Systems, Inc. (EBRCZ) Stock Analysis

EBR Systems, Inc. (EBRCZ) Healthcare & Pipeline Overview

EBR Systems, Inc., founded in 2003, develops and markets the WiSE cardiac resynchronization therapy (CRT) system, a wireless, leadless pacing solution for heart failure patients. The company addresses limitations of traditional lead-based pacemakers, focusing on reducing complications and improving patient outcomes within the medical specialties sector.

What Is the Investment Thesis for EBRCZ?

The company's wireless pacing technology addresses the limitations of traditional lead-based systems, offering a potential solution to reduce lead-related complications and improve patient outcomes. With a market capitalization of $140M, EBR Systems operates in the medical specialties sector, characterized by ongoing demand for advanced cardiac therapies. Key growth catalysts include expanding clinical evidence supporting the efficacy and safety of the WiSE system, securing regulatory approvals in key markets, and increasing adoption by cardiologists. The company's gross margin of 45.2% indicates potential for profitability as revenue scales. Potential risks include competition from established players in the cardiac rhythm management market and the need for continued innovation to maintain a competitive edge.

Based on FMP financials and quantitative analysis

EBRCZ Key Highlights

Market capitalization of $140M reflects investor valuation of EBR Systems' growth potential in the cardiac rhythm management market.

• Gross margin of 45.2% demonstrates the company's ability to generate revenue efficiently from its WiSE CRT system.
• Beta of 0.38 indicates lower volatility compared to the overall market, suggesting a relatively stable investment.
• The company operates with 89 employees, indicating a focused and lean organizational structure.
• Negative P/E ratio of -4.92 reflects current lack of profitability, but also highlights the growth stage of the company.

Who Are EBRCZ's Competitors?

EBRCZ is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are EBRCZ's Key Strengths?

Innovative wireless pacing technology.

• Potential to reduce lead-related complications.
• Strong intellectual property protection.
• First-mover advantage in the wireless CRT market.

What Are EBRCZ's Weaknesses?

Limited market share compared to established players.

• Reliance on a single product (WiSE system).
• Negative profitability.
• OTC market trading.

What Could Drive EBRCZ Stock Higher?

Clinical trials and post-market studies demonstrating the efficacy and safety of the WiSE system.

• Expansion into new geographic markets through regulatory approvals and commercial partnerships.
• Development of new applications for the WiSE technology beyond cardiac resynchronization therapy.
• Strategic partnerships with hospitals and cardiac centers to establish centers of excellence for wireless cardiac pacing.
• Securing reimbursement coverage for the WiSE system from government and private payers.

What Are the Key Risks for EBRCZ?

Financial-distress signal — its Altman Z-Score of -0.30 sits in the distress zone (elevated bankruptcy risk).

• Competition from established players in the cardiac rhythm management market.
• Regulatory hurdles and reimbursement challenges.
• Technological advancements by competitors.
• Product liability claims.
• Risks associated with trading on the OTC market, including limited liquidity and price volatility.

What Are the Growth Opportunities for EBRCZ?

• Expansion into new geographic markets represents a significant growth opportunity for EBR Systems. The company can pursue regulatory approvals and commercial partnerships in regions such as Europe, Asia-Pacific, and Latin America to expand the reach of its WiSE CRT system. Timeline: Ongoing.
• Development of new applications for the WiSE technology beyond cardiac resynchronization therapy could unlock additional growth opportunities. The company can explore the use of its wireless pacing technology in other areas of cardiac electrophysiology, such as atrial fibrillation and heart block. This would broaden the company's product portfolio and address a wider range of patient needs. Timeline: Ongoing.
• Increasing clinical evidence supporting the efficacy and safety of the WiSE system is crucial for driving adoption by cardiologists. EBR Systems can invest in clinical trials and post-market studies to demonstrate the benefits of its wireless pacing technology compared to traditional lead-based systems. Positive clinical data can help to build confidence among physicians and increase the utilization of the WiSE system. Timeline: Ongoing.
• Strategic partnerships with hospitals and cardiac centers can accelerate the adoption of the WiSE system. EBR Systems can collaborate with leading medical institutions to establish centers of excellence for wireless cardiac pacing. These partnerships can provide training and support for physicians, as well as generate awareness and referrals for the WiSE system. Timeline: Ongoing.
• Securing reimbursement coverage for the WiSE system from government and private payers is essential for ensuring patient access and driving revenue growth. EBR Systems can work with healthcare authorities and insurance companies to demonstrate the cost-effectiveness and clinical value of its wireless pacing technology. Favorable reimbursement policies can help to make the WiSE system more affordable and accessible to patients. Timeline: Ongoing.

What Are EBRCZ's Competitive Advantages?

• Proprietary wireless technology that differentiates it from competitors.
• Strong intellectual property portfolio protecting its innovations.
• Established relationships with key opinion leaders in the field of cardiac electrophysiology.
• First-mover advantage in the wireless cardiac pacing market.

What Does EBRCZ Do?

EBR Systems, Inc., established in 2003 and headquartered in Sunnyvale, California, is a medical technology company focused on developing and commercializing innovative solutions for cardiac rhythm management. The company's core product is the WiSE (Wireless Stimulation Endocardially) cardiac resynchronization therapy (CRT) system. This system utilizes a proprietary wireless technology to deliver pacing stimulation directly to the inside of the left ventricle of the heart, offering a leadless alternative to traditional CRT devices. Traditional CRT systems rely on leads that are placed through the veins to deliver electrical impulses to the heart. These leads can be prone to complications such as dislodgement, infection, and lead fracture, requiring additional procedures for replacement or removal. EBR Systems' WiSE technology aims to eliminate these lead-related complications, improving patient outcomes and reducing the need for re-interventions. The WiSE system is designed to provide a more physiological and effective form of CRT, particularly for patients who have failed to respond to traditional lead-based systems or who are not candidates for lead placement. EBR Systems is committed to advancing the field of cardiac rhythm management through its innovative wireless pacing technology.

What Products and Services Does EBRCZ Offer?

• Develops wireless cardiac pacing technology.
• Offers the WiSE cardiac resynchronization therapy (CRT) system.
• Provides a leadless alternative to traditional CRT devices.
• Aims to reduce lead-related complications in cardiac pacing.
• Delivers pacing stimulation directly to the inside of the left ventricle.
• Focuses on improving patient outcomes in cardiac rhythm management.
• Eliminates the need for leads, reducing the risk of dislodgement and infection.

How Does EBRCZ Make Money?

• Develops and manufactures the WiSE CRT system.
• Sells the WiSE system to hospitals and cardiac centers.
• Provides training and support to physicians on the use of the WiSE system.
• Generates revenue through the sale of its medical devices.

What Industry Does EBRCZ Operate In?

EBR Systems operates within the medical specialties industry, specifically focusing on cardiac rhythm management. The market for cardiac resynchronization therapy (CRT) is driven by the increasing prevalence of heart failure and the need for effective treatment options. The competitive landscape includes established players such as Medtronic, Boston Scientific, and Abbott, which offer traditional lead-based CRT systems. EBR Systems differentiates itself through its wireless WiSE technology, which addresses the limitations and complications associated with traditional leads. The global cardiac rhythm management market is projected to grow, driven by technological advancements and an aging population.

Who Are EBRCZ's Key Customers?

• Hospitals and cardiac centers that perform cardiac resynchronization therapy.
• Cardiologists who specialize in cardiac rhythm management.
• Patients with heart failure who are candidates for CRT.
• Medical professionals seeking leadless pacing solutions.

Company Profile

EBR Systems, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Sunnyvale, US. The company is led by CEO John Graham McCutcheon. EBRCZ has traded publicly since 2023.

Key Financial Metrics

Return on assets is -68.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -56.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.7%, the inverse of the P/E and a quick read on earnings relative to price.

EBRCZ Valuation & Market Position

With a $140M market cap, EBR Systems, Inc. sits in the micro-cap segment of the market.

Quarterly Financial Performance: EBR Systems, Inc.

Revenue for EBR Systems, Inc. came in at $2.6M during Q2 FY2026, a 9.7% improvement versus the preceding quarter. The company recorded a net loss of $17.0M, with diluted EPS of $-0.03. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, EBRCZ averaged $-0.03 in diluted EPS.

EBR Systems, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.30 places it in the distress zone, a signal of elevated financial risk.

EBR Systems, Inc. has beaten Wall Street's EPS estimate in 5 of its last 7 reported quarters — more hits than misses. Reported results have landed about 238.9% below estimates on average.

The most recent 3 insider filings for EBR Systems, Inc. break down as 1 sales and 2 purchases. On net that is roughly 7.7M shares acquired (about $20.8M) — insiders putting money in tends to read as conviction.

EBRCZ Financials

EBRCZ Latest News

No recent news available for EBRCZ.

EBRCZ Analyst Consensus

EBRCZ MoonshotScore

EBRCZ Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources